Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Resistant Hypertension by Prevention of T-Cell Co-Stimulation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women 18 to 65 years of age with hypertension, treated with three or more anti-hypertensive drugs, one being a diuretic, and~* having a systolic blood pressure \>150 mmHg in the clinic and daytime average \>150 mmHg on ambulatory blood pressure monitoring~Exclusion Criteria:~* Medical history of secondary cause of hypertension, severe obesity (BMI \>35), severe psychiatric disorders, cancer in the last 5 years other than nonmelanoma skin cell cancers, herpes zoster or cytomegalovirus that resolved less than 2 months before~* Inability to return for abatacept treatment and follow-up for 24 weeks.~* Inability to understand or complete study-related assessments.~* Current abuse of drugs or alcohol.~* Receipt of any live vaccines within 3 months of the anticipated first dose of study medication.~* Evidence of active or latent bacterial or viral infections at the time of potential enrollment, including human immunodeficiency virus (HIV)~* Risk for tuberculosis~* Abnormal laboratory values including positive hepatitis B surface antigen, hemoglobin \< 8.5 g/dL, white blood cell count \< 3000/mm3, platelets \< 100,000/mm3, creatinine \> 2.5 times the upper limit of normal (ULN), alanine aminotransferase or aspartate aminotransferase \> 2 times the ULN.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- abatacept (Type: ACTIVE_COMPARATOR): Subjects randomized to abatacept weighing 60 to 100 kg will receive 750 mg, and those \>100 kg will receive 1000 mg abatacept by intravenous infusion at 0 \[randomization\], 2, and 4 weeks and then every 4 weeks thereafter for a total of 24 weeks.~All subjects will be treated with chlorthalidone 25 mg/day, lisinopril 20 mg/day \[Patients with a history of adverse reaction to lisinopril will be treated with losartan 50 mg/day\], amlodipine 5 mg/day and spironolactone 25 mg bid as standardized treatment of hypertension prior to randomization and throughout the active treatment phase.
- placebo (Type: PLACEBO_COMPARATOR): Subjects randomized to placebo will receive 100 ml normal saline by intravenous infusion at 0 \[randomization\], 2, and 4 weeks and then every 4 weeks thereafter for a total of 24 weeks.~All subjects will be treated with chlorthalidone 25 mg/day, lisinopril 20 mg/day \[Patients with a history of adverse reaction to lisinopril will be treated with losartan 50 mg/day\], amlodipine 5 mg/day and spironolactone 25 mg bid as standardized treatment of hypertension prior to randomization and throughout the active treatment phase.

Based on this trial design, predict the completion outcome and termination type (if applicable).